Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Ulotaront hydrochloride by Otsuka Pharmaceutical for Generalized Anxiety Disorder (GAD): Likelihood of Approval
Ulotaront hydrochloride is under clinical development by Otsuka Pharmaceutical and currently in Phase III for Generalized Anxiety Disorder (GAD). According...
Ulotaront hydrochloride by Sumitomo Pharma America for Schizophrenia: Likelihood of Approval
Ulotaront hydrochloride is under clinical development by Sumitomo Pharma America and currently in Phase III for Schizophrenia. According to GlobalData,...
Ulotaront hydrochloride by Sumitomo Pharma America for Generalized Anxiety Disorder (GAD): Likelihood of Approval
Ulotaront hydrochloride is under clinical development by Sumitomo Pharma America and currently in Phase III for Generalized Anxiety Disorder (GAD)....